Transdermal 17β estradiol

Phase 2Small molecule

UUniversiti Kebangsaan Malaysia Medical Centre

Transdermal 17β estradiol is one of 20 small molecule programs targeting Turner syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Turner SyndromeActive, not recruiting

Turner SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Turner Syndrome

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

1 2

Depo-Provera

Eli Lilly

Phase 3

1 3

Micronized Progesterone

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Approved

1 4

Estinyl

OOrganon and Co

Phase 3

1 5

R-Hgh

Merck & Co.

Approved

1 6

Voxzogo

BioMarin Pharmaceutical

Phase 2

1 7

Oestrogen

Novo Nordisk

Approved

1 8

Growth Hormone

Pfizer

Phase 2

2 9

Estradiol Valerate

Bayer

Phase 2

1 10

Oxandrolone

PPar Pharmaceutical, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Not yet recruiting

Turner Syndrome

NCT07041814

Clinical

Trials by Indication[1]

Turner syndrome1 trial

A Study Comparing Different Treatment Approaches for the Initiation of Puberty in Girls With Turner Syndrome Using a TRIFECTA-DARED Approach for Rare Diseases

Not yet recruiting·UUniversiti Kebangsaan Malaysia Medical Centre·Phase 2·NCT07041814·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Transdermal 17β estradiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Transdermal 17β estradiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Transdermal 17β estradiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universiti Kebangsaan Malaysia Medical Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversiti Kebangsaan Malaysia Medical Centre

Transdermal 17β estradiol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Turner syndrome1 trial

References

Drug Info

Quick Facts

Related News